Q-omics provides the consensus-scored BCRP3 profile across patient tissues and cancer cell-line models. BCRP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCRP3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, BCRP3 RNA expression shows 15,471 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where BCRP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCRP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCRP3 survival associations across molecular data types. BCRP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCRP3 RNA expression–survival associations across cancer types. High BCRP3 expression shows unfavorable associations in KIRC, ACC and LUSC, but favorable associations in LUAD, CESC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCRP3 RNA expression.
This table summarizes BCRP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BCRP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCRP3 shows lower tumor expression in KICH, LUSC, LUAD and KIRC and higher tumor expression in HNSC and THCA. The KICH box plot shows higher BCRP3 RNA expression in normal versus tumor tissue (log2 FC = −2.212, t-test p < 0.001).
This table shows molecular features associated with BCRP3 in patient tissues and cancer cell lines. In patient samples, BCRP3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
